| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Lin,Zhi-Hui | Chairman | 13.78% | SYNMOSA BIOPHARMA CORPORATION |
| Qiu,Hui-Lan | Director | 13.78% | SYNMOSA BIOPHARMA CORPORATION |
| ZHONG JIA CONSULTANT CO., LTD. | Director | 0.00% | |
| Zhong,Wei-Lian | Director | 0.00% | |
| Hao,Wei-Hua | Director | 1.35% | |
| Guo,Han-Bin | Director | 0.00% | |
| Ceng,Xue-Ru | Independent Director | 0.00% | |
| Lin,Gu-Tong | Independent Director | 0.00% | |
| Fang,Li-Xing | Independent Director | 0.00% |
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 23,165 | 46,073 | 29,133 |
| Operating cost | 10,349 | 28,616 | 29,510 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 12,816 | 17,457 | -377 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 12,816 | 17,457 | -377 |
| Operating expenses | 53,442 | 82,296 | 92,951 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -40,626 | -64,839 | -93,328 |
| Non-operating income and expenses | -1,915 | -5,992 | -9,853 |
| Net profit (loss) before tax | -42,541 | -70,831 | -103,181 |
| Income tax expense (benefits) | - | - | - |
| Net profit (loss) of ongoing business for the current period | -42,541 | -70,831 | -103,181 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -42,541 | -70,831 | -103,181 |
| Other comprehensive profit (loss), net | - | 16 | 276 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -42,541 | -70,815 | -102,905 |
| Net profit (loss) attributable to owners of parent company | - | - | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | - | - | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 0 | -1 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | - | - | - |
| Net cash inflows (outflows) from investing activities | - | - | - |
| Net cash inflow (outflow) from financing activities | - | - | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | - | - | - |
| Beginning balance of cash and cash equivalents | - | - | - |
| Ending balance of cash and cash equivalents | - | - | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 157,250 | 188,993 | 136,738 |
| Non-current asset | 320,817 | 335,203 | 352,573 |
| Total asset | 478,067 | 524,196 | 489,311 |
| Current liability | 41,253 | 33,948 | 39,129 |
| Non-current liability | 3,113 | 14,701 | 19,178 |
| Total liability | 44,366 | 48,649 | 58,307 |
| share capital | 949,836 | 949,966 | 868,361 |
| Equity - secruity token | - | - | - |
| capital reserve | 336 | 34,168 | 774 |
| retained earning | -516,399 | -507,835 | -437,476 |
| Other equity | -72 | -752 | -655 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | - | - | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 433,701 | 475,547 | 431,004 |
| Share capital awaiting retirement (unit: share) | 4,500 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 4 | 5 | 4 |
